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ABSTRACT
To study the relative abundance and the changes of both estrogen receptor alpha (ERa) and ERb mRNA before
and after ovariectomy in major organs important to the regulation of calcium homeostasis, we compared the
degree of mRNA expression of ERa to that of ERb in rat tissues by performing competitive reverse transcription
polymerase chain reaction (RT-PCR) with internal standards. Both ERa and ERb were highly expressed in the
ovary {ERa[(2.2 ± 0.33) × 107 copies/µg of total RNA] > ERb[(1.2 ± 0.33) × 105 copies/µg of total RNA]} as we
expected. The bone marrow and renal cortex were very important target organs of estrogen because ERa was
highly expressed ~ 2 × 105 copies/µg of total RNA, but marrow cells revealed only a very weak expression of ERb
[(0.7 ± 0.21) × 102 copies/µg of total RNA]. Both ERa and ERb were expressed in the trabecular bone [(3.2 ± 0.56)
× 103 copy/µg of RNA] and [(2.8 ± 0.21) × 102 copy/µg of RNA], respectively. However, they were not detected in
the cortical bone. In the jejunum, the expression of ERa was not detectable, while ERb was expressed very weakly
[(1.1 ± 0.24) × 102 copies/µg of total RNA]. The thyroid gland expressed low copy numbers of ERb [(6.0 ± 0.23) ×
102 copies/µg of total RNA], but the parathyroid gland was negative for both ERa and ERb mRNA. In cultured
stromal cells, ERa and ERb mRNAs were not detected after a 24-h culture; however, the rates of mRNA
expression of ERa and ERb reached ~ 105 copies/µg of total RNA and ~ 102 copies/µg of total RNA, respectively,
after 9-, 11-, and 13-day cultures. After ovariectomy, the expression of ERa mRNA decreased abruptly in the bone
marrow and renal cortex, and both ERa and ERb were barely detected in the trabecular bone. In conclusion, ERa
might be the main ER in organs important for calcium homeostasis, except in the jejunum. The mRNA expression
of ERa in the bone marrow and renal cortex decreased abruptly after ovariectomy, which may partially explain
why the effect of estrogen deficiency can be amplified and why trabecular bone loss is more predominant than
cortical bone loss shortly after surgical or natural menopause. (J Bone Miner Res 1999;14:1189–1196)
INTRODUCTION
UNTIL RECENTLY, only one type of estrogen receptor(ER) had been identified and the tissue selective ef-
fects of estrogen-like molecules have been postulated to
involve receptor-associated proteins and/or variations in
promoter responsive elements.(1) A novel type of ER
(ERb) was discovered recently and it was found to bind
estradiol (E2) with relatively high affinity and to be capable
of activating transcription of a reported gene in the pres-
ence of this ligand.(2–4) However, it is still very hard to find
major differences between two receptors and the roles of
ERb in the presence of ERa at the same cell.(5) Further-
more, several alternatively spliced ERb isoforms have also
been reported.(6) Therefore, the presence of these two ERs
and their isoforms provided more complexity in under-
standing the pathophysiology of bone loss after menopause.
Estrogen and selective estrogen receptor modulator
(SERM) revealed the selective actions of estrogen in dif-
ferent target tissues.(7,8) Recently, Pan et al. reported that
ovariectomy induced increased bone resorption and an in-
creased number of osteoclasts per millimeter of trabecular
bone surface in ERa knock-out mice.(9) The ERa knock-
out mice model might reveal some compensatory role of
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ERb in the maintenance of bone mass. Paech et al. showed
that antiestrogens, but not 17b-estradiol, can activate a re-
porter gene downstream of an AP1 site, when ERb inter-
acts with AP1. Both antiestrogens and 17b-estradiol acti-
vated the reporter gene when ERa was present instead of
ERb.(10) Their observation suggested that ERa and ERb
could produce opposite effects in some circumstances.
Therefore, the existence of two ERs presents another po-
tential source of tissue-specific estrogen regulation. How-
ever, the two receptors have strikingly similar properties in
most settings, so the roles of ERb in the presence of ERa
in the same cell remain a puzzle.(5)
Upon interaction with estrogen, ER undergoes a confor-
mational change permitting the displacement of inhibitory
proteins.(11) The receptor then spontaneously dimerizes
and acquires the ability to interact with specific DNA re-
sponses of target organs. ERa and ERb can be dimerized in
several forms such as ERa and ERa, ERa and ERb, and
ERb and ERb.(12) The existence of three forms of homo- or
heterodimer suggested that different target tissues might
respond differently to estrogens or SERMs according to
varying ratios of ERa and ERb. Therefore, it is crucial to
know the degree of expression of each ER and the changes
of ER expression before and after ovariectomy in organs
which are important for the regulation of calcium metabo-
lism, and which might provide some clues to help explain
the accelerated bone loss after menopause.
In this study, we compared the degree of mRNA expres-
sion of ERa with that of ERb in each organ and analyzed
the changes in their expression 3 weeks after ovariectomy
by competitive RT-PCR with 30 bp–deleted internal con-
trol mRNA. We found the bone marrow and renal cortex
were very important target organs for estrogen and the
expression of ERa in both organs was undetectable 3 weeks
after ovariectomy. ERb was also not expressed exclusively
in the organs important for regulation of calcium homeo-
stasis, except in the jejunum.
MATERIALS AND METHODS
Materials
Female Sprague-Dawley rats (6–8 weeks old) (Charles
River Japan, Co., Tokyo, Japan) were used in this study.
Rats were randomly divided into two groups, one ovariec-
tomized (OVX) (n 4 12 rats) the other non-OVX (n 4 6
rats). Three weeks later, half of the OVX and all non-OVX
rats were sacrificed by cervical dislocation under light ether
anesthesia. The remaining OVX rats were then treated with
17b-estradiol (30 mg/kg) for 1 week and sacrificed by the
same procedure. The level of serum E2 was 21.2 ± 3.5 pg/ml
and 3.1 ± 0.74 pg/ml in control and OVX rats, respectively.
The increase of body weight in OVX rats was greater than
that of controls 4 weeks after ovariectomy (from 210 ± 22 g
to 298 ± 26 g vs. from 203 ± 20 g to 270 ± 24 g, respectively).
Cell culture
Bone marrow stromal cells were cultured as described
previously.(13) The rats were killed by cervical dislocation,
and tibiae were aseptically removed and dissected free of
adhering tissues. The bone ends were cut off with scissors
and the cavity was flushed with 1 ml of alpha modified
essential medium (a-MEM) by slow injection from one end
of the bone using a sterile 26 G needle. The medium with
flushed bone marrow was centrifuged at 1400 rpm for 10
minutes. Cell pellets were resuspended in culture medium
and layered on the Ficoll/Hypaque (specific gravity 1.077)
(Pharmacia Biotech, Uppsala, Sweden). After centrifuga-
tion at 1400 rpm for 30 minutes, an enriched bone marrow
stromal cell fraction was obtained from the interface of the
culture medium and the Ficoll/Hypaque layer. The cells
were seeded into a 35 mm tissue culture dish at a density of
4 × 105 cells/cm2 and cultured in a-MEM containing 10%
FBS, penicillin, and streptomycin (100 U/ml and 100 mg/ml,
respectively). The medium was changed twice weekly from
the second week. When the cells were grown to 80% con-
fluence, they were subcultured using conventional tech-
niques employing 0.01% trypsin and 0.05% EDTA.
Design of oligonucleotide
The oligonucleotide ERa forward primer-1: 58AATT-
T A A T A C G A C T C A C T A T A G G G A / A A T T C T -
GACAATCGACGCCAG and ERa reverse primer-1:
5 8CGCTT/GTGCTTCAAC-ATTCTCCCTCCTC/
TGCCCACTTCGTAACACTTGCG were used for the
construction of ERa standard template DNA. The oligo-
nucleotide ERa forward primer-2: 58AATTCTGACAAT-
CGACGCCAG (+472 relative to ATG) and the ERa re-
verse primer-2: 58GTGCTTCAACATTCTCCCTCCTC
(+794 relative to ATG) were used for amplification of a
344-bp fragment of the rat ERa mRNA as previously re-
ported.(14) The oligonucleotide ERb forward primer-1:
58AATTTAATACGACTCACTATAGGGA/TTCCCG-
GCAGCACCAGTAACC and the ERb reverse primer:
58GAGCA/TCCCTCTTTGC-GTTTGGACTA/TCAG-
TGTCTCTCTGTTTACAGG were used for the con-
struction of ERb internal standard-template DNA. The
oligonucleotide ERb forward primer-2: 58TTCCCG-
GCAGCACCAGTAACC (+38 relative to ATG) and the
ERb reverse primer-2: 58TCCCTCTTTGCGTTTGGA-
CTA (+279 relative to ATG) were used for amplification of
a 262-bp fragment of the ERb mRNA.
Construction of the standard ERa and ERb
template DNA
Total RNA was extracted from the rat ovary and RT-
PCR was performed by the standard method for getting
ERa and ERb template DNA. Figure 1 schematically de-
picts the principle and steps involved in generating internal
standards which were used as competitors for RT-PCR of
human ERa or ERb. To prepare internal standard DNAs,
RT was done with each forward primer-1 and reverse
primer-1 of ERa or ERb as explained below. The purified
RNA (0.3 mg) and RNAse free distilled water (2.5 ml) were
boiled for 4 minutes at 94°C in a 500 ml microcentrifuge
tube, then chilled on ice for ~ 1–2 minutes. After a brief spin,
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the following reagents were added to the tube: 1 ml of ran-
dom hexamers, 1 ml of DTT(100 mM), 4 ml of 5× RT buffer,
8 ml of dNTP(25 mM), 0.5 ml of RNAsin, 1 ml of AMV RT.
The mixture was incubated at 37°C for 10 minutes, then at
42°C for 45–60 minutes. The reaction was stopped by boil-
ing for 4 minutes at 94°C, then chilled on ice. Thirty-five
cycles of PCR were done as explained below. The following
reagents were added to a 500 ml microcentrifuge tube: 10 ml
of RTproduct, 2 ml of MgCl2 (25 mM), 4 ml of 10× PCR
buffer, 1 ml of forward primer, 1 ml of reverse primer, 0.3 ml
of Taq polymerase, and 33.7 ml of DW. The reaction mix-
ture was pulse centrifuged, and PCR amplification was car-
ried out in a DNA Thermal Cycler (Perkin Elmer Cetus,
Norwalk, CT, U.S.A.). The prepared samples were dena-
tured at 95°C for 3 minutes. Each cycle consisted of 1
minute denaturization at 95°C, 2 minutes annealing at 52°C,
and 3 minutes at 72°C for enzyme extension. The RT-PCR
product was run on an agarose gel, and the DNA band was
extracted using a DNA purification kit (Qiagen, Inc.,
Chatsworth, CA, U.S.A.). The synthesized template DNA
had the sequence downstream of the T7 promotor at the 58
end and contained a 30 bp deletion that ended 28 bp (ERa)
or 26 bp (ERb) from the C-terminal end, respectively.
In vitro transcription for synthesis of internal
standard ERa or ERb mRNA
The extracted DNA was transcribed using T7 RNA poly-
merase applying the Riboprobe in vitro Transcription Sys-
tem (Promega, Co., Madison, WI, U.S.A.). The RNA con-
centration was determined by spectrophotometry.
Purification of total RNA
Female Sprague-Dawley rats (6–8 weeks old) were sac-
rificed by cervical dislocation and tissue was collected. Can-
cellous bone was surgically collected from the distal me-
taphysis, and cortical bone was collected from the distal
diaphysis. Tissue samples were immediately processed for
total RNA isolation. Total RNA of each tissue or cultured
marrow stromal cells was extracted by using RNeasy Mini
kit (Qiagen). Only RNA samples exhibiting an A260/A280
ratio >1.6 and showing integrity of the RNA by electropho-
resis were used in further experiments. After quantitation,
RNA was diluted to 100 ng/ml in diethylpyrocarbonate
(DEPC) H2O for RT-PCR. Before RT-PCR analysis, total
RNA was electrophoresed on a 1% formaldehyde agarose
gel to check for intact 28S and 18S ribosomal bands. All
experiments were approved by this Institute’s Animal Care
Committee.
Competitive RT-PCR
Competitive RT-PCR was done as explained below. The
following reagents were added to a 500 ml microcentrifuge:
14.8 ml of DW, 3 ml of 10× buffer, 3 ml of 2 mM dNTP, 3 ml
of 10 pmol each primer (forward primer 2 and reverse
primer 2), 1.5 ml of 100 mM DTT, 0.3 ml RNAsin, 0.3 ml of
AMV RT, 0.1 ml of Taq polymerase, 3 ml (300 ng) of ex-
tracted tissue RNA, and 1 ml of internal standard mRNA.
The mixture was incubated at 42°C for 60 minutes and was
stopped by boiling for 5 minutes at 95°C. Thirty-three
cycles of PCR were done continuously. Each cycle con-
sisted of 1 minute denaturization at 94°C, 1.5 minutes an-
nealing at 62°C, and 2 minutes extension at 72°C for en-
FIG. 1. Synthesis of ER-internal standard cDNA. The sequence of the forward primer-1 was as follows: 58-T7 promotor
sequence (25 bp) + forward primer-2 (21 bp), and the sequence of the reverse primer-1 was as follows: 58-CGCTT(5 bp)
+ reverse primer-2[21 bp (ERa) or 23 bp (ERb)] + d (22 bp). The c (30 bp) fragment was deleted in the newly synthesized
ER-internal standard cDNA.
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zyme extension. The cycling was followed by a final
extension at 72°C for 5 minutes. All samples were added to
1 ml 10× loading dye and size was fractionated by electro-
phoresis in a 3.5% meta-agarose gel. Visualization after
ethidium bromide staining (30 minutes in 0.5 mg) was per-
formed by Polaroid MP-4 camera (Clifton, NJ, U.S.A.) and
the amount of DNA band was analyzed. The RNA was
serially diluted from 0 to 107 copy/ml (0, 103, 104, 105, 106,
and 107 copy/ml, respectively). The RT reaction for b-actin
was performed at 65°C for 25 minutes followed by a two-
step PCR reaction (95°C 10 s, 65°C 20 s) in 2.2 mM MgCl2
for 33 cycles.(15) Products were visualized by running 10 ml
of 100 ml total reaction volume on a 3.5% metaphor-
agarose/1× TBE gel for 1.5 h at 100 V. The copy number of
internal standard mRNA was calculated as:
copies/ml = OD260 · 40~ng/ml! · 10
- 9
· 6
· 1023/~standard bp · 660!
After titration of the copy number of internal standard
mRNA, 1 ml of mRNA (from 0 to 107 copies/ml) was added
to each tube for the RT-PCR reaction. Products were visu-
alized by running 10 ml of 100 ml total reaction volume on
a 3.5% metaphor-agarose/1× TBE gel for 1.5 h at 100 V. To
confirm whether nonvisualized products in 3.5% metaphor-
agarose gel are not expressed at all, we repeated RT-PCR
without any internal standard mRNA several times. The
results were expressed as the mean ± SE from six observa-
tions.
RESULTS
Construction of standard ERa and ERb
template DNA
ERa and ERb template DNA were constructed through
RT-PCR by using the forward primer-1 designed to have
the T7 promotor sequence at the 58 end and the reverse
primer-1 designed to generate 30 bp (c portion in Fig. 1)
deletion that ended 28 bp (ERa) or 26 bp (ERb) from the
C-terminal end, respectively. After quantitation, RNA was
diluted to 300 ng/ml in DEPC H2O for RT-PCR.
RT-PCR of ovarian ERa and ERb
A RT mixture was amplified for 15, 20, 25, 30, 33, or 35
cycles with the specific primers, respectively. After 33
cycles, the rate of amplification decreased gradually and it
approached a plateau at 35 cycles (data not shown). Thirty-
three cycles were found to be the most appropriate because
amplification under those conditions was within the linear
range and was also submaximal. All experiments described
hereafter employed amplification for 33 cycles. Internal
standard cDNA amplifications competed with target cDNA
amplification. A 345 bp ERa and a 315 bp ERa-internal
standard cDNA were obtained by using both ERa-forward
primer-2 and ERa-reverse primer-2 (Fig. 2, lane 1). A 262
bp ERb and a 232 bp ERb-internal standard cDNA were
obtained by using both ERb-forward primer-2 and ERb-
reverse primer-2 (Fig. 2, lane 3). In addition, RT-PCR using
b-actin primers was performed on all RNA samples as a
control for tube-to-tube variability and differences in the
amount of RNA (Fig. 2, lanes 2 and 4).
Competitive RT-PCR
Compared with ERb, a significantly high expression of
the ERa gene was detected in the ovary (Fig. 3 and Table
1). ERa was expressed in the ovary [(2.2 ± 0.33) × 107
copies/mg (RNA), renal cortex [(3.1 ± 0.32) × 105 copy/
copies/mg of RNA], bone marrow [(2.3 ± 0.24) × 105 copies/
mg of RNA] and uterus [(3.3 ± 0.43) × 103 copies/mg of
RNA]. ERb was expressed in the ovary [(1.2 ± 0.33) × 105
copies/mg of RNA], thyroid [(6.0 ± 0.23) × 102 copies/mg of
RNA], and jejunum [(1.1 ± 0.24) × 102 copies/mg of RNA].
After ovariectomy, the expression of ERa was undetect-
able in the bone marrow and it dropped markedly to nearly
1/1000th of the pre-OVX value in the renal cortex (Fig. 4).
However, we could not see any remarkable change of ERa
expression in the uterus. In contrast to the change of ERa
FIG. 3. Competitive RT-PCR from the ovary using each
forward primer-2 and each reverse primer-2 with a serial
copy number of ERa or ERb internal standard m-RNA. M,
size marker (F × 174/HaeIII).
FIG. 2. RT-PCR from total RNA of the ovary using each
forward primer-2 and each reverse primer-2 with ERa or
ERb internal standard m-RNA. Lane 1, ERa (345 bp) and
ERa internal standards (315 bp); lanes 2 and 4, b-actin
internal standard; M, size marker (F × 174/HaeIII); lane 3,
ERb (262 bp) and ERb internal standard (232 bp).
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expression, there was no change in the expression of ERb
in the jejunum or thyroid after ovariectomy. One week af-
ter 17b-estradiol (30 mg/kg) treatment, the rates of ERa
expression in the bone marrow and renal cortex increased
by 20–30 times of the pretreatment value. However, we
could not find any significant change of ERb expression in
both organs (data not shown).
Expression of ER in trabecular and cortical bone
The rates of ERa and ERb mRNA expression were ana-
lyzed in trabecular and cortical bone. Trabecular bone was
surgically collected from the distal metaphysis, and cortical
bone was collected from the distal diaphysis. Both ERa and
ERb were expressed in the trabecular bone [(3.2 ± 0.56) ×
103 copy/mg of RNA] and [(2.8 ± 0.21) × 103 copy/mg of
RNA], respectively. However, they were not detected in
the cortical bone. After ovariectomy, both ERa and ERb
were hardly detected in the trabecular bone.
Expression of ER in cultured marrow stromal cells
ERa and ERb mRNA were not detected after a 24-h
bone marrow stromal cell culture; however, the rates of
mRNA expression of ERa and ERb reached ~ 105 copies/
mg of total RNA and ~ 102 copies/mg of total RNA, respec-
TABLE 1. EXPRESSION OF ERa AND ERb IN RAT TISSUES BEFORE AND AFTER OVARIECTOMY
Alpha Beta
Before OVX After OVX Before OVX After OVX
Duodenum — — — —
Jejunum — — (1.1 ± 0.24) × 102 (1.2 ± 0.35) × 102
Ileum — — — —
Renal cortex (3.1 ± 0.32) × 105 (3.2 ± 0.23) × 102 — —
Marrow stroma (2.3 ± 0.24) × 105 — (0.7 ± 0.21) × 102 —
Ovary (2.2 ± 0.33) × 107 (1.2 ± 0.33) × 105
Uterus (3.3 ± 0.43) × 103 (3.3 ± 0.34) × 103 (0.7 ± 0.31) × 102 —
Thyroid — — (6.0 ± 0.23) × 102 (2.4 ± 0.37) × 103
Parathyroid — — — —
Trabecular bone (3.2 ± 0.56) × 103 — (2.8 ± 0.21) × 103 —
Cortical bone — — — —
Copies/mg of total RNA.
FIG. 4. Competitive RT-PCR from the different tissues using each forward primer-2 and each reverse primer-2 with a
serial copy number of ERa or ERb internal standard m-RNA. M, size marker (F × 174/HaeIII).
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tively, after 9-, 11-, and 13-day cultures (Table 2). To make
certain whether they were not expressed at all after a 24-h
culture, we repeated RT-PCR several times without adding
any internal standard mRNA.
DISCUSSION
The second estrogen receptor (ERb) was cloned from a
rat prostate cDNA library; however, it has been hard to find
major differences between ERa and ERb.(2,15,16) The for-
mation of a heterodimeric complex between ERa and
ERb, recently observed by Pettersson et al. might consti-
tute a hitherto unrecognized mechanism involved in the
tissue type– and cell type–specific effects of estrogens and
certain antiestrogens.(17) Therefore, it is crucial to study the
degree of expression of each ER and the changes of ER
expression before and after ovariectomy in organs involved
in the regulation of calcium metabolism to understand the
potential physiologic implications of this effect on bone.
Since antibodies against ERb are not yet available, we stud-
ied the expression of ERa and ERb mRNA in each organ
and we also studied the change of expression of both
mRNAs in these organs 3 weeks after ovariectomy by com-
petitive RT-PCR. In this study, we showed clearly that
there was a relative abundance of ERa mRNA expression
in the bone marrow and renal cortex, and its expression
decreased abruptly after ovariectomy. Our system was
quantitative, and it was clear that the relative distribution of
both ER subtypes was quite different.
ERa and ERb were expressed abundantly in the ovary as
reported previously.(14,18) An interesting finding was that
bone marrow was one of the important target organs of
estrogen; however, the degree of ERb expression was much
lower than that of ERa. A previous immunoelectron mi-
croscopic study also revealed that most of the electron-
dense reaction was observed in many mononuclear cells
located in the marrow stroma(19) and that some ER-
positive cells were situated in the hematopoietic tissue.(18)
There was a change of time course in the mRNA expression
of both ERa and ERb in the primary culture of bone mar-
row stromal cells. Both ERa and ERb were not detected
after a 24-h culture; however, the rates of mRNA expres-
sion of ERa and ERb reached ~ 105 copies/mg of total RNA
and ~ 102 copies/mg of total RNA, respectively, after 9-, 11-,
and 13-day cultures. Marrow stromal cells, osteoblast and
osteoclast precursor cells were mixed up in this culture sys-
tem. Onoe et al. also reported that there was time course of
change in mRNA expression of ERa and ERb in primary
osteoblastic cells during differentiation into mature osteo-
blasts.(20) Therefore, antiresorptive effects of estrogen
could be mediated by indirect effect through binding to
ERa on bone marrow stromal cells and by the direct effects
through binding to both ERa and ERb on differentiated
osteoblast and osteoclast cells. Numbers of pre-B cells
changed dramatically and reciprocally in response to estro-
gen levels in mice, suggesting that normal lymphophoiesis
might be under hormonal control.(21) Increased prolifera-
tion of osteoclast precursor cells after ovariectomy(22) or
clonal expansion of B-cell precursors followed by bone loss
after estrogen deficiency in mice, which could be mimicked
by repletion of interleukin (IL)-7 in cultured B cell precur-
sors, may possibly be the crucial evidence of our story.(23)
ERa was expressed in the renal cortex, which is another
important organ for regulating calcium homeostasis, and
the degree of expression was very high [(2.3 ± 0.24) × 105
copies/mg of RNA]. However, ERb was not expressed at all
in contrast to the abundant expression of ERa. A previous
study performed by immunohistochemical technique
showed that ER was expressed not in tubular epithelial cells
but in interstitial cells, capillaries, arteries, and renal cap-
sules.(24) However, because calcium is reabsorbed through
tubular epithelial cells and immunohistochemical technique
is not a sensitive method if the rate of expression is low, it
is therefore necessary that further studies be undertaken to
confirm whether ERa is expressed in tubular epithelial cells
or not. Parathyroid hormone performs the central role in
the regulation of calcium homeostasis in mammals; how-
ever, the parathyroid gland was not a target organ of estro-
gen because both ERa and ERb were not expressed in this
study.
The degree of ERb expression was very low in the jeju-
num [(1.1 ± 0.24)102 copies/mg of RNA]. However, both
receptors were not detected in the duodenum and ileum in
our system. ERa was not detectable in the jejunum, which
differed from other findings. We extracted total RNA from
the whole layer of jejunum, not just from the mucosal layer.
Therefore, if the total copy number of ERa was extremely
low, it may not have been detected in our study. However,
we could compare the relative abundance of ERb to that of
ERa in the jejunum. Our results also reconfirmed that ep-
ithelial cells in the jejunum, which is an important site for
calcium absorption, contained ER capable of regulating
gene transcription for stimulating intestinal calcium absorp-
tion or enhancing the uptake of calcium after treatment of
17b-estradiol in vitro.(25) The thyroid gland was one of the
target organs of estrogen as ERb, not ERa, was expressed
in low abundance. Given the higher incidence and better
prognosis of thyroid cancer in women, there were sugges-
tions that this lesion may be influenced by sex hormones
without any supporting evidence about the presence of ER
in thyroid cancer.(26) Here we found that ERb was ex-
pressed in the thyroid gland and its expression was not
affected by ovariectomy at all. This may indicate that es-
trogen regulates the proliferation or differentiation of thy-
TABLE 2. mRNA EXPRESSION OF ERa AND ERb IN
CULTURED MARROW STROMAL CELLS
Culture period
ER
Alpha Beta
24 h — —
9 days (0.7 ± 0.13) × 105 (1.1 ± 0.25) × 102
11 days (1.2 ± 0.24) × 105 (1.5 ± 0.32) × 102
13 days (1.3 ± 0.32) × 105 (1.1 ± 0.14) × 102
Copies/mg of total RNA.
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roid cells or performs some other potential roles providing
a better prognosis of thyroid cancer through ERb.
Both ERa and ERb were expressed in the trabecular
bone; however, the rate of ERb expression was weak, [(3.2
± 0.56) × 103 copy/mg of RNA] and [(0.8 ± 0.21) × 102
copy/mg of RNA], respectively. Recently, a lack of ER was
reported to lead to a failure of growth plate to close, as well
as to osteoporosis.(9,27,28) These estrogen receptor-alpha
knockout (ERKO) human and mice models brought us in
agreement with our findings that ERa was the main ER in
the bone marrow, kidney, and even bone.(27,28) If ERb was
expressed sufficiently or as the main ER in these organs,
ERb should compensate for the lack of ERa and bone mass
should be preserved in ERKO human and mice. Therefore,
it can be further evidence that ERa is the main ER in these
organs.
The change of ERa expression after ovariectomy was
interesting. Most receptors are up-regulated after with-
drawal of ligands, with some exceptions.(29) The expression
of ERa in bone marrow was undetectable and its expres-
sion in the renal cortex dropped markedly 3 weeks after
ovariectomy. Recently, the molecular basis of ER regula-
tion of the IL-6 promotor has been determined.(30) Osteo-
clast formation was decreased by the inhibition of IL-6, and
estrogen withdrawal stimulated the proliferation of hema-
topoietic osteoclast precursors originating from cells of the
granulocyte macrophage colony stimulating unit or macro-
phage colony stimulating unit lineage.(22) Therefore, the
effects of estrogen deficiency in bone marrow should be
amplified by the near-complete suppression of ERa at the
transcription level following ovariectomy, and it explains
why bone loss is accelerated just after surgical menopause
or the early natural postmenopausal period. Meanwhile,
the expression of both receptors in the uterus was low, and
we failed to provide data demonstrating the effectiveness of
ovariectomy on ER expression in the uterus. We could not
explain these results clearly. One plausible explanation
might be that the expression of ER was measured in the
whole uterus, not in endometrium in this study, and the
complete down-regulation of ER after ovariectomy might
not be biologically relevant in the uterus. We were unable
to observe the changes of ERb expression in the jejunum
and thyroid gland shortly after ovariectomy. To clarify the
biologic significance of such changes of mRNA expression
of ER after ovariectomy in different target tissues, further
studies about the transcriptional regulation of the ERa and
ERb gene in different tissues should be undertaken. In ad-
dition, the long-term changes of the degree of ER expres-
sion after ovariectomy should be also studied in various
tissues.
In conclusion, ERa was the main ER in organs important
for calcium homeostasis, except in the jejunum; the bone
marrow and renal cortex highly expressing ERa were the
most important target organs for estrogen; and the expres-
sion of ERa was undetectable in the bone marrow, and its
expression in the renal cortex dropped markedly 3 weeks
after ovariectomy. Our findings may partially explain the
reason why the rate of bone loss, especially in trabecular
bone, is accelerated and the bony effect of estrogen defi-
ciency is amplified after surgical or natural menopause.
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